Home Shop Oxamflatin

Oxamflatin

ALX-270-379

Datasheet
Manual
SDS
CofA

Already have an account?

HDAC inhibitor

Potent inhibitor of mammalian HDACs (histone deacetylases) (IC₅₀=15.7nM). Acts as a ligand for the enzyme active site metal ion. Upregulates plasminogen activator inhibitor type 2 (PAI-2) expression with concomitant inhibition of urokinase (u-PA) gene and protein expression in HT-1080 and U-937 cells. Elevates the expression of extracellular matrix proteins fibronectin and gelsolin. Induces apoptosis in P-glyoprotein (Pgp) positive and Pgp negative multidrug resistant cells.

Shipping: Available products typically ship within 24/48h, via priority shipping.

Do you need support? Contact Customer Service or Technical Support.

Online Account
Access or Create Your Account

Product Details

Alternative Name	(2E)-5-[3-(Phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic acid
Appearance	Tan to yellow solid.
CAS	151720-43-3
Couple Target	HDAC
Couple Type	Inhibitor
Formula	C₁₇H₁₄N₂O₄S
MW	342.4
Purity	≥95% (HPLC)
Solubility	Soluble in DMSO, methanol or acetonitrile.

Handling & Storage

Use/Stability	As indicated on product label or CoA when stored as recommended.
Handling	Protect from light. Packaged under inert gas. After reconstitution, prepare aliquots and store at -20°C.
Long Term Storage	+4°C
Shipping	Blue Ice

Regulatory Status	RUO – Research Use Only

Oxamflatin treatment enhances cloned porcine embryo development and nuclear reprogramming: Mao, J., Zhao, M. T., et al.; Cell. Reprogram. 17, 28 (2015), Abstract
Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells: K. Huber, et al.; J. Biol. Chem. 286, 22211 (2011), Abstract — Full Text
Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors: MacTavish, H., Diallo, J. S., et al.; PLoS One 5, e14462 (2011), Abstract
Novel mechanisms of apoptosis induced by histone deacetylase inhibitors: M.J. Peart, et al.; Cancer Res. 63, 4460 (2003), Abstract
The novel anti-tumour agent oxamflatin differentially regulates urokinase and plasminogen activator inhibitor type 2 expression and inhibits urokinase-mediated proteolytic activity: A.E. Dear & R.L. Medcalf; Biochim. Biophys. Acta 1492, 15 (2000), Abstract
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase: Y.B. Kim, et al.; Oncogene 18, 2461 (1999), Abstract
Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD: H. Sonoda, et al.; Oncogene 13, 143 (1996), Abstract

Datasheet, Manuals, SDS & CofA

Manuals And Inserts

Datasheet

Certificate of Analysis

Please enter the lot number as featured on the product label

Lot No. :

SDS

Enzo Life Science provides GHS Compliant SDS

English (EU) SDS

If your language is not available please fill out the SDS request form

Your Cart

Your Cart

Oxamflatin

ALX-270-379

Product Details

Handling & Storage

Datasheet, Manuals, SDS & CofA

Manuals And Inserts

Certificate of Analysis

SDS

Change Country

Tell us about You

Tell us about your paper

Tell us about You

Tell us about your project